2009
HIV infection in the elderly
Gebo KA, Justice A. HIV infection in the elderly. Current Infectious Disease Reports 2009, 11: 246-254. PMID: 19366568, PMCID: PMC3129647, DOI: 10.1007/s11908-009-0036-0.Peer-Reviewed Original ResearchOlder patientsYounger patientsBetter virologic suppressionOlder HIV patientsActive antiretroviral therapyManagement of HIVPrevalence of HIVDrug-drug interactionsAntiretroviral regimenHAART initiationHAART regimenVirologic suppressionAntiretroviral therapyHIV patientsImmunologic benefitsHIV infectionPatientsSide effectsHIVPopulation agesRegimenAgeHAARTComorbiditiesTherapy
2008
Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies
Harris RJ, Sterne J, Abgrall S, Dabis F, Reiss P, Saag M, Phillips AN, Chêne G, Gill JM, Justice AC, Rockstroh J, Sabin CA, Mocroft A, Bucher HC, Hogg RS, Monforte AD, May M, Egger M. Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies. Antiviral Therapy 2008, 13: 959-967. PMID: 19195321, PMCID: PMC4507810, DOI: 10.1177/135965350801300802.Peer-Reviewed Original ResearchConceptsHIV type-1-infected patientsMild anemiaAntiretroviral therapyHemoglobin levelsAdjusted hazard ratioMonths of HAARTStart of HAARTActive antiretroviral therapyT-cell countsPrevalence of anemiaProspective cohort studyLong-term prognosisBaseline anemiaAIDS eventsHazard ratioCohort studyPrognostic importancePrognostic valueProspective studyUntreated individualsPatientsAnemiaHigh mortalityHAARTNormal hemoglobin
2007
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies
May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiébaut R, Gill J, Phillips A, Reiss P, Hogg R, Ledergerber B, D'Arminio Monforte A, Schmeisser N, Staszewski S, Egger M. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007, 21: 1185-1197. PMID: 17502729, PMCID: PMC3460385, DOI: 10.1097/qad.0b013e328133f285.Peer-Reviewed Original ResearchConceptsStart of HAARTCD4 cell countCell countHIV-1 RNA levelsHIV-1-infected patientsInitiation of HAARTTreatment-naive patientsDiagnosis of AIDSInjection drug useVirological responseHIV careNew AIDSCumulative incidenceParametric survival modelsClinical stageProspective studyRisk calculatorHAARTProgression rateTreatment changesPatientsDrug usePrognostic modelAIDSCells/
2006
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis
May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, Fätkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. The Lancet 2006, 368: 451-458. PMID: 16890831, DOI: 10.1016/s0140-6736(06)69152-6.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapyCD4 cell countAntiretroviral therapyHazard ratioTreatment responseTreatment-naive HIV-1-infected adultsCell countHIV-1-infected adultsMedian CD4 cell countHIV-1 RNA copiesCharacteristics of patientsHIV-1 RNAShort-term prognosisHIV treatment responseProportion of womenPrimary endpointVirological responseCohort studyHIV infectionCox regressionHAARTPatientsRNA copiesCorresponding figurePrognosis
2005
Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America
Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, Dabis F, Reiss P, Kirk O, Bernasconi E, Grabar S, Justice A, Staszewski S, Fätkenheuer G, Sterne JA. Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America. Clinical Infectious Diseases 2005, 41: 1772-1782. PMID: 16288403, DOI: 10.1086/498315.Peer-Reviewed Original ResearchConceptsIncidence of tuberculosisMonths of HAARTMultivariable analysisMultivariable Poisson regression modelsInitiation of HAARTLevel of immunodeficiencyLower baseline CD4Active antiretroviral therapyHIV RNA levelsRisk of tuberculosisInjection drug usersMode of transmissionPoisson regression modelsBaseline CD4HAART initiationHigher CD4Antiretroviral therapyTB epidemicIncidence rateCopies/HAARTDrug usersPatientsTuberculosisCD4The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy
d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, Dabis F, Grabar S, Ledergerber B, Gill J, Reiss P, Egger M. The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy. JAMA Internal Medicine 2005, 165: 416-423. PMID: 15738371, DOI: 10.1001/archinte.165.4.416.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapyAIDS eventsAntiretroviral therapyViral etiologyRate of declineAntiretroviral-naive individualsRates of AIDSIncidence of AIDSCohort CollaborationCD4 countMonths 0Different etiologiesFungal etiologyChanging IncidenceHAARTPoisson regressionEtiologyIncidenceRNA levelsAIDSViral eventsTherapyMonths